Search by Drug Name or NDC
NDC 64980-0406-03 Efavirenz 50 mg/1 Details
Efavirenz 50 mg/1
Efavirenz is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Rising Pharma Holdings, Inc.. The primary component is EFAVIRENZ.
MedlinePlus Drug Summary
Efavirenz is used along with other medications to treat human immunodeficiency virus (HIV) infection. Efavirenz is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by decreasing the amount of HIV in the blood. Although efavirenz does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Related Packages: 64980-0406-03Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Efavirenz
Product Information
| NDC | 64980-0406 |
|---|---|
| Product ID | 64980-406_ef5feaa1-6aff-47fc-9a9b-6ead5518b699 |
| Associated GPIs | 12109030000110 |
| GCN Sequence Number | 040655 |
| GCN Sequence Number Description | efavirenz CAPSULE 50 MG ORAL |
| HIC3 | W5K |
| HIC3 Description | ANTIVIRALS, HIV-SPECIFIC, NON-NUCLEOSIDE, RTI |
| GCN | 43301 |
| HICL Sequence Number | 018748 |
| HICL Sequence Number Description | EFAVIRENZ |
| Brand/Generic | Generic |
| Proprietary Name | Efavirenz |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Efavirenz |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 50 |
| Active Ingredient Units | mg/1 |
| Substance Name | EFAVIRENZ |
| Labeler Name | Rising Pharma Holdings, Inc. |
| Pharmaceutical Class | Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 3A Inducers [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcri |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA078064 |
| Listing Certified Through | 2025-12-31 |
Package
NDC 64980-0406-03 (64980040603)
| NDC Package Code | 64980-406-03 |
|---|---|
| Billing NDC | 64980040603 |
| Package | 30 CAPSULE in 1 BOTTLE (64980-406-03) |
| Marketing Start Date | 2017-12-15 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |